ELTX

MKT CAP:$217M

Elicio Therapeutics, Inc.

Market Cap

$217M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$11.85+$3.80 (+47.20%)

Apr 23, 2026

Company Details

Elicio Therapeutics, Inc., a clinical-stage biotechnology company, engages in developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases. The company's lead product candidate is ELI-002, an AMP therapeutic...

CEO

Robert T. Connelly

IPO Date

Feb 5, 2021

Website

elicio.com

Key Metrics TTM

Revenue

$0

— YoY

Net Income

-$40M

EPS (Diluted)

-$2.58

Free Cash Flow

-$37M

Revenue / Share

$0.00

Gross Margin

—

Operating Margin

—

Net Margin

—

FCF Margin

—

P/S

—

P/E

—

Earnings Reports

Q1 2026

May 12, 2026

PENDING

FY 2025

Mar 12, 2026

$0EPS -$2.58

Q4 2025

Mar 12, 2026

$0EPS -$0.45

Q3 2025

Nov 13, 2025

$0EPS -$0.60

Q2 2025

Aug 7, 2025

$0EPS -$0.66

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q1 22	$2M	$1M	-$14M
Q2 22	$0	$0	-$6M
Q3 22	$0	$0	-$6M
Q4 22	$0	-$294.0K	-$6M
Q1 23	$0	$0	-$8M
Q2 23	$0	$0	-$8M
Q3 23	$0	$0	-$11M
Q4 23	$0	-$286.0K	-$9M
Q1 24	$0	-$290.0K	-$10M
Q2 24	$0	-$293.0K	-$11M
Q3 24	$0	-$290.0K	-$10M
Q4 24	$0	-$305.0K	-$13M
Q1 25	$0	-$278.0K	-$11M
Q2 25	$0	$0	-$10M
Q3 25	$0	-$283.0K	-$8M
Q4 25	$0	-$286.0K	-$9M

Valuation

Quarter	P/S	P/E
Q1 22	1.9x	—
Q2 22	1.9x	—
Q3 22	2.1x	—
Q4 22	34.3x	—
Q1 23	—	—
Q2 23	—	—
Q3 23	—	—
Q4 23	—	—
Q1 24	—	—
Q2 24	—	—
Q3 24	—	—
Q4 24	—	—
Q1 25	—	—
Q2 25	—	—
Q3 25	—	—
Q4 25	—	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 22	-$16M	-$16M
Q2 22	$6M	$6M
Q3 22	-$5M	-$5M
Q4 22	-$7M	-$7M
Q1 23	-$8M	-$8M
Q2 23	-$10M	-$10M
Q3 23	-$5M	-$5M
Q4 23	-$10M	-$10M
Q1 24	-$12M	-$12M
Q2 24	-$9M	-$9M
Q3 24	-$7M	-$7M
Q4 24	-$9M	-$9M
Q1 25	-$10M	-$10M
Q2 25	-$9M	-$9M
Q3 25	-$11M	-$11M
Q4 25	-$7M	-$7M

Capital Expenditures

Quarter	CapEx
Q1 22	$0
Q2 22	$559.0K
Q3 22	$0
Q4 22	$95.0K
Q1 23	$17.0K
Q2 23	$21.0K
Q3 23	$45.0K
Q4 23	$0
Q1 24	$0
Q2 24	$42.0K
Q3 24	$0
Q4 24	$45.0K
Q1 25	$0
Q2 25	$0
Q3 25	$0
Q4 25	$16.0K

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 22	—	+160.5%
Q2 22	-100.0%	-66.8%
Q3 22	-100.0%	-66.5%
Q4 22	-100.0%	-47.3%
Q1 23	-100.0%	-51.6%
Q2 23	—	+24.8%
Q3 23	—	+86.7%
Q4 23	—	+57.6%
Q1 24	—	+31.2%
Q2 24	—	+40.5%
Q3 24	—	-4.0%
Q4 24	—	+43.5%
Q1 25	—	+4.8%
Q2 25	—	-7.6%
Q3 25	—	-22.2%
Q4 25	—	-34.4%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 22	$0	0.0%
Q2 22	$0	—
Q3 22	$110.0K	—
Q4 22	$0	—
Q1 23	$224.0K	—
Q2 23	$0	—
Q3 23	$339.0K	—
Q4 23	$337.0K	—
Q1 24	$324.0K	—
Q2 24	$350.0K	—
Q3 24	$327.0K	—
Q4 24	$464.0K	—
Q1 25	$517.0K	—
Q2 25	$710.0K	—
Q3 25	$698.0K	—
Q4 25	$772.0K	—

OpEx Breakdown

Quarter	R&D	G&A	S&M	SG&A
Q1 22	$12M	$2M	$3M	—
Q2 22	$5M	$1M	—	—
Q3 22	$5M	$1M	—	—
Q4 22	$4M	—	—	$2M
Q1 23	$5M	$2M	—	—
Q2 23	$5M	$3M	—	—
Q3 23	$7M	$4M	—	—
Q4 23	$6M	$3M	—	—
Q1 24	$8M	$3M	—	—
Q2 24	$8M	$3M	—	—
Q3 24	$7M	$3M	—	—
Q4 24	$11M	—	—	$3M
Q1 25	$8M	$3M	—	—
Q2 25	$7M	$3M	—	—
Q3 25	$5M	—	—	$3M
Q4 25	$5M	$4M	—	—

War Chest

Quarter	Cash	Short-term Investments	Total
Q4 21	$89M	$0	$89M
Q1 22	$73M	$0	$73M
Q3 22	$55M	$0	$55M
Q4 22	$8M	$0	$8M
Q1 23	$29M	$0	$29M
Q2 23	$22M	$0	$22M
Q3 23	$15M	$0	$15M
Q4 23	$13M	$0	$13M
Q1 24	$12M	$0	$12M
Q2 24	$4M	$0	$4M
Q3 24	$26M	$0	$26M
Q4 24	$18M	$0	$18M
Q1 25	$18M	$0	$18M
Q2 25	$22M	$0	$22M
Q3 25	$21M	$0	$21M
Q4 25	$19M	$0	$19M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q1 22	3M	+0.0%	-77.5%
Q2 22	3M	+3.0%	+4.0%
Q3 22	3M	+2.9%	+6.4%
Q4 22	3M	-2.4%	+3.5%
Q1 23	3M	+3.2%	+6.8%
Q2 23	3M	-3.1%	+0.5%
Q3 23	4M	+31.5%	+28.5%
Q4 23	10M	+135.5%	+209.8%
Q1 24	10M	+7.0%	+221.1%
Q2 24	11M	+9.8%	+263.9%
Q3 24	14M	+20.4%	+233.0%
Q4 24	12M	-10.2%	+27.1%
Q1 25	13M	+6.1%	+26.1%
Q2 25	16M	+24.0%	+42.3%
Q3 25	17M	+3.9%	+22.9%
Q4 25	15M	-8.3%	+25.5%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q1 22	—	—
Q2 22	—	—
Q3 22	—	—
Q4 22	—	—
Q1 23	—	—
Q2 23	—	—
Q3 23	—	—
Q4 23	—	—
Q1 24	—	—
Q2 24	—	—
Q3 24	—	—
Q4 24	$0	32
Q1 25	$0	32
Q2 25	$0	32
Q3 25	$0	32
Q4 25	$0	200K

Revenue / Employee